Instructions for use Nazoferon nasal drops 100,000 IU/ml glass bottle 5 ml
Composition
active ingredient: interferon alfa-2b;
1 ml of drops contains 100,000 IU of recombinant human interferon alpha-2b;
Excipients: trometamol, trometamol hydrochloride, hypromellose, disodium edetate, lysine hydrochloride, potassium chloride, methyl parahydroxybenzoate (E 218), water for injections.
Dosage form
Nasal drops.
Main physicochemical properties: clear colorless liquid.
Pharmacotherapeutic group
Immunostimulants. Interferons. Interferon alpha-2b. ATX code L03A B05.
Pharmacological properties
Pharmacodynamics
NAZOFERON is an antiviral, antimicrobial, anti-inflammatory, immunomodulatory, antiproliferative agent. The biological action of interferon is characterized by the following effects: antiviral - inhibits the replication of viruses (adenoviruses, influenza viruses) due to the inhibitory effect on the processes of transcription and translation; antiproliferative - inhibits the reproduction of cells (most DNA- and RNA-containing viruses). Interferon initiates the synthesis of a specific enzyme - protein kinase, which prevents translation due to the phosphorylation of one of the initiating factors of this process; activates a specific ribonuclease, which damages the viral matrix RNA. The effects of interferon also include: stimulation of the production of other cytokines, induction of specific enzymes, inhibition of cell proliferation, immunomodulation (enhancement of the phagocytic activity of macrophages and specific cytotoxicity of lymphocytes towards target cells). Interferon is a mediator of immunity, has pronounced tissue specificity, and protects the body from pathogens of infectious diseases.
Pharmacokinetics
Not studied.
Indication
Prevention and treatment of acute respiratory viral infections (ARVI) in children aged 1 year and older and adults:
in patients who often and for a long time suffer from upper respiratory tract diseases; in contact with patients with SARS; in hypothermia; with seasonal increase in morbidity in organized groups (children's and adults), among "risk" groups - medical workers, teachers, especially during the epidemic.
Contraindication
Hypersensitivity to interferon alfa-2b and other components of the drug, history of severe allergic diseases. Pregnancy or breastfeeding.
Interaction with other medicinal products and other types of interactions
The simultaneous use of intranasal vasoconstrictor drugs is not recommended, as they contribute to dryness of the nasal mucosa.
Application features
The drug should be injected into each nasal passage.
Before using the drug, you should lie on your back or sit, tilt your head back slightly and turn it towards the nasal passage into which the drops will be instilled, and, without touching the dropper bottle to the inner walls of the nose, instill the drug. Immediately after instillation, it is recommended to massage the wings of the nose with your fingers from the outside for several minutes to evenly distribute the drug over the nasal mucosa.
The use of drops for children should be carried out under adult supervision.
The drug contains methyl parahydroxybenzoate, which may cause allergic reactions, including delayed ones, and in exceptional cases, bronchospasm.
The drug should not be used if the integrity and labeling of the package is broken, if the physical properties (color or transparency of the liquid) change, and after the expiration date.
To avoid the spread of infection, individual use is recommended.
Avoid contact of the drug with the mucous membrane of the eyes.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Use during pregnancy or breastfeeding
Use is contraindicated.
Method of administration and doses
At the first signs of SARS (within 5 days)
Children aged 1 month to 1 year - 1 drop in each nasal passage 5 times a day (single dose - 8000 IU, daily dose - 40000 IU);
Children aged 1 to 3 years - 2 drops in each nasal passage 3-4 times a day (single dose - 16,000 IU, daily dose - 48,000-64,000 IU);
Children aged 3 to 14 years - 2 drops in each nasal passage 4-5 times a day (single dose - 16,000 IU, daily dose - 64,000-80,000 IU);
Children aged 14 to 18 years - 2 drops in each nasal passage 5-6 times a day (single dose - 16,000 IU, daily dose - 80,000-96,000 IU);
Adults – 3 drops in each nasal passage 5-6 times a day (single dose – 24,000 IU, daily dose – 120,000-144,000 IU).
For the prevention of respiratory viral infections
In case of contact with a sick person and hypothermia - according to the age dosage 2 times a day for 5-7 days. If necessary, repeat the preventive courses. In case of single contact, a single application is sufficient.
With a seasonal increase in incidence - according to the age-appropriate dosage, once in the morning with an interval of 1-2 days.
Remove the protective cap from the bottle. Turn the bottle with the nozzle down and before using the drops for the first time, make a few test presses on the pump-dispenser. Place the end of the nozzle in each nasal passage in turn and press the pump-dispenser the required number of times according to the dosage. After use, close the bottle with the cap.
Children
Use in children from 1 month of age.
Overdose
Not studied.
Adverse reactions
In rare cases, skin rashes.
In case of adverse reactions, you should consult a doctor.
Expiration date
3 years.
Shelf life after opening the bottle, if stored at a temperature of 2°C to 8°C (in a refrigerator), is 10 days.
Do not use the drug after the expiration date indicated on the package.
Storage conditions
Store in a place protected from light at a temperature of 2 ° C to 8 ° C. Keep out of the reach of children.
Packaging
5 ml in glass vials with dropper caps. 1 vial per pack.
Vacation category
Without a prescription.
Producer
JSC "Farmak".
Location of the manufacturer and its business address
Ukraine, 04080, Kyiv, Kyrylivska St., 74.
